Abstract
Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS).
Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV).
We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768